Abstract
Peritoneal metastases (PM) represent one of the most refractory disease states. It frequently develops in patients (pts) with gastric (GC) or pancreatic (PC) cancer, significantly impacting their prognosis. Many types of systematic chemotherapies have been evaluated for PC but the results were not satisfactory. Recently, the use of intraperitoneal paclitaxel (ipPTX) plus systemic chemotherapy for GC with PM has shown promising clinical results, especially in pts who underwent conversion surgery after the disappearance of PM due to ipPTX (Ishigami H, et al.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
